Crestline Management LP purchased a new position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 35,973 shares of the biopharmaceutical company’s stock, valued at approximately $4,302,000. Alexion Pharmaceuticals makes up about 0.4% of Crestline Management LP’s portfolio, making the stock its 18th biggest holding.
Several other large investors have also added to or reduced their stakes in ALXN. Delpha Capital Management LLC acquired a new position in shares of Alexion Pharmaceuticals in the fourth quarter worth about $102,000. Valeo Financial Advisors LLC acquired a new position in shares of Alexion Pharmaceuticals in the third quarter worth about $147,000. Dupont Capital Management Corp bought a new stake in Alexion Pharmaceuticals in the third quarter valued at about $156,000. Beacon Investment Advisory Services Inc. bought a new stake in Alexion Pharmaceuticals in the third quarter valued at about $201,000. Finally, Invictus RG bought a new stake in Alexion Pharmaceuticals in the third quarter valued at about $202,000. Institutional investors and hedge funds own 95.38% of the company’s stock.
In related news, EVP John B. Moriarty sold 1,261 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $147,864.86. Following the completion of the transaction, the executive vice president now directly owns 20,210 shares of the company’s stock, valued at approximately $2,369,824.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ludwig Hantson sold 2,553 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the transaction, the chief executive officer now directly owns 36,172 shares of the company’s stock, valued at $4,399,600.36. The disclosure for this sale can be found here. Insiders have sold 31,253 shares of company stock valued at $3,656,229 over the last ninety days. Corporate insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals, Inc. (ALXN) traded up $0.62 during trading hours on Wednesday, hitting $121.70. The stock had a trading volume of 89,497 shares, compared to its average volume of 1,989,210. The company has a market capitalization of $26,840.00, a price-to-earnings ratio of 55.80, a PEG ratio of 1.18 and a beta of 1.13. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.09 by $0.39. The company had revenue of $909.70 million during the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.26 earnings per share. sell-side analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Crestline Management LP Takes Position in Alexion Pharmaceuticals, Inc. (ALXN)” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/14/crestline-management-lp-takes-position-in-alexion-pharmaceuticals-inc-alxn.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.